Becoming active in adulthood can curb risk of dying from certain health issues by 22%, study finds
Health experts, scientists, and medical organisations agree that physical activity benefits both the body and the mind. What has been less clear is exactly how much exercise helps, which patterns of activity are most effective, and at which stages of life they are most important.
The new study published in the British Journal of Sports Medicine (BJSM) aimed to answer those questions by identifying how physical activity during adulthood can influence the risk of dying from heart disease, cancer, and other health issues.
Researchers analysed data from 85 studies of varying size. The number of participants per study ranged from 357 to over 6.5 million participants.
Overall, the analysis found that exercising in adulthood can yield significant health benefits, reducing the risk of mortality by 20 per cent to 40 per cent.
Specifically, adults who are regularly active can curb these risks by up to 30 per cent to 40 per cent.
And even those who transition from an inactive to an active lifestyle can reduce their risk of death from any cause by approximately 22 per cent.
Exercise does not appear to reduce all health risks equally. For example, it was tied to a 30 per cent to 40 per cent lower risk of death from heart disease, but the links to cancer mortality were less clear.
Interestingly, not all types of exercise had the same effect on adults' health.
The paper suggests that adults who work out in their spare time can reduce their health risks more than people who are active by happenstance at work or home.
Some experts argue that the relationship between fitness and mortality risk is a little more nuanced than the latest study suggests.
'Based on these types of studies, we cannot very confidently say to what extent this lower mortality risk is due to the differences in activity or other factors that differ,' Marcel Ballin, who researches physical activity and health at Uppsala University in Sweden, told Euronews Next.
That could include genetics and environmental exposures that influence people's health and well-being.
For example, a study published in the European Journal of Epidemiology earlier this year found that genetics plays a significant role in mortality risk. While physical activity was relevant, longevity reflects people's overall health, not just that one factor, the study found.
Ballin suggested the latest findings should be taken with a grain of salt.
'What we can say is that if you are belonging to a group that is more active than the average, and you're consistently being active or increasing your activity over time, it seems to be good for your mortality risk,' he said.
'But, we need to be more careful when attributing the lower mortality to the activity itself,' he added.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
Douglas E. Williams, Ph.D. Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics ('Draig'), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO). Dr Williams brings more than 30 years of experience in the biopharmaceutical sector, having held executive leadership and board roles across some of the industry's most innovative companies including Biogen, ZymoGenetics, Amgen and Seattle Genetics and contributed to the development of several blockbusters therapies, including Enbrel®, Tecfidera® and Spinraza®. Ruth McKernan, Interim CEO and founder of Draig Therapeutics, said, 'Douglas's exceptional track record of developing innovative therapies and driving strategic growth makes him an ideal leader for our Board. I could not be more delighted. The Company looks forward to benefitting from his leadership and guidance in delivering transformative neuropsychiatric therapies.' 'I am honoured to take on the role of Chair as Draig Therapeutics advances its exciting pipeline into the next phases of clinical development,' said Douglas E. Williams, incoming Chair of Draig Therapeutics. 'More effective therapies for major depressive disorder and other neuropsychiatric disorders remain significant unmet needs for millions of people worldwide. Draig's scientific approach to develop novel medicines for these patients is both compelling and differentiated, and I look forward to working closely with the board and its exceptional leadership team to support the Company achieve its goals.' Most recently, Dr Williams served as the President of R&D at Sana Biotechnology, a leading cell therapy company. Prior to joining Sana, he was the founding CEO of Codiak Biosciences, where he led the company through several private financing rounds as well as a successful initial public offering. Previously, Dr Williams was Executive Vice President (EVP) of Research and Development at Biogen where he played a key role in advancing multiple programmes. Before joining Biogen, he was CEO and a board member at ZymoGenetics, where he led the company through its acquisition by Bristol Myers Squibb in 2010. Earlier in his career, Dr Williams held senior leadership roles at several prominent biotech companies, including Chief Scientific Officer and EVP R&D at Seattle Genetics (Seagen, acquired by Pfizer in 2023 for $43 billion), and Senior VP and Washington Site Leader at Amgen. He spent over a decade at Immunex, where he served as EVP and Chief Technology Officer, and was a member of the Board of Directors. Dr Williams currently serves on the boards of numerous biotechnology companies, including Climb Bio (Chair) and CAMP4 Therapeutics, eGenesis and Stablix (Director). He has also previously been Chair or Director on the boards of multiple private and public companies in the US and Europe over the past 30 years, including CytoImmune Therapeutics, Xenikos, Array Biopharma, AC Immune, Ovid Therapeutics, Ironwood Pharmaceuticals and Regulus Therapeutics, among others. ENDS For further information: Mark Swallow, Sandi GreenwoodE-mail: draigtx@ Draig TherapeuticsE-mail: rmckernan@ About Draig TherapeuticsDraig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders' unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD). Draig is the Welsh word for 'dragon' and it reflects the company's origins in Wales. The name and logo were inspired by this heritage, reflecting its scientific roots stemming from Cardiff University. Draig was co-founded by Cardiff University and SV Health Investors, which led the seed financing with ICG, and is backed by other leading healthcare venture firms including Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures and Schroders Capital. For more information, please visit Attachment Douglas E. Williams, Ph.D. Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
Mum-of-two wants to find stranger who 'saved her life' in work meeting
A cancer researcher who developed the disease herself is hoping to find the stranger who saved her life. Emma Hawke was at a work meeting when a dermatologist she had never met before spotted a suspicious mole on her arm and urged her to get it checked. She was subsequently diagnosed with melanoma - the most serious form of skin cancer. Cancer researcher Emma Hawke was at a work meeting when a doctor spotted a suspicious mole on her arm (Image: Cancer Research UK) Emma, a 42-year-old mother-of-two from Eastleigh, said: "I was watching TV when the phone rang. I thought it was going to be a family member calling, but it was the hospital. "My melanoma diagnosis was a huge shock and I immediately expected to need chemotherapy or immunotherapy. "My sons were just five and eight at the time and I feared they were going to see me becoming really poorly. 'Thankfully it was caught early enough to be managed with surgery and it hadn't spread to my lymph nodes. "I do have a scar on my arm where they had to take a large enough area of skin to safely remove all the cancerous cells, but I would have gone through so much more treatment or worse had I left it. "I would love to find the doctor who spotted it and say thanks for saving my life." Former skin cancer patient Emma Hawke is urging people to stay safe by using plenty of sun cream (Image: Getty Images) Emma is also working to raise awareness of skin cancer. She has joined forces with Cancer Research UK and NIVEA Sun to encourage people across the south to seek shade, cover up, and apply sunscreen regularly. "Awareness of the risks of UV radiation was low when I was younger, and I'd put oil on try to look tanned like the popstars of the 90s," she said. 'Now, I make sure I'm covered up and take some time out of the sun in the middle of the day as well as always being prepared with a hat, sunglasses, and sunscreen. "Sun safety doesn't mean missing out, just being careful whether you're at home or abroad.' READ MORE: Southampton cancer vaccine trial expands for melanoma patients Cancer Research UK health information manager Beth Vincent added: "Getting sunburnt just once every two years can triple the risk of developing skin cancer compared to never being burnt. "Even on a cloudy day, the sun can be strong enough to burn between mid-March and mid-October."
Yahoo
35 minutes ago
- Yahoo
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. "With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis." "We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step." "We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area." AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties. About AATec Medical AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit and follow AATec on LinkedIn. About Northway Biotech Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit Northway Biotech Contact: Prof. Vladas Algirdas BumelisCEO and Chairman of the AATec Medical Contact: Dr. Rüdiger Jankowsky, CEOinfo@ Media Contact: MC ServicesKatja Arnold, Julia von Hummelaatec-medical@ Phone: +49 (0)89 2102280 SOURCE: Northway Biotech View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data